piracetam has been researched along with Chronic Disease in 33 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To clarify the effect of levetiracetam (LEV) for acute and chronic seizure control in acute encephalitis with refractory, repetitive partial seizures (AERRPS)." | 7.81 | Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase. ( Imamura, A; Maegaki, Y; Maruta, K; Matsunami, K; Narita, A; Nishimura, Y; Ohno, K; Saiki, Y; Saito, Y; Sokota, T; Sugihara, S; Tamasaki, A; Ueda, R, 2015) |
| "Levetiracetam was a probable cause of depression in these 2 elderly patients." | 7.75 | Probable levetiracetam-associated depression in the elderly: two case reports. ( Bainbridge, JL; Linnebur, SA; Vande Griend, JP, 2009) |
| "Piracetam has been shown to improve speech in aphasic patients." | 6.40 | The role of piracetam in the treatment of acute and chronic aphasia. ( Huber, W, 1999) |
| "To clarify the effect of levetiracetam (LEV) for acute and chronic seizure control in acute encephalitis with refractory, repetitive partial seizures (AERRPS)." | 3.81 | Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase. ( Imamura, A; Maegaki, Y; Maruta, K; Matsunami, K; Narita, A; Nishimura, Y; Ohno, K; Saiki, Y; Saito, Y; Sokota, T; Sugihara, S; Tamasaki, A; Ueda, R, 2015) |
| "Levetiracetam (LEV, 2S-(oxo-1-pyrrolidinyl)butanamide, Keppra, UCB Pharma) is a new anti-epileptic drug used to treat certain types of seizures in epilepsy patients." | 3.76 | Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats. ( Choi, HC; Choi, SY; Jo, SM; Kang, TC; Kim, DS; Kim, JE; Kim, YI; Song, HK, 2010) |
| "Levetiracetam was a probable cause of depression in these 2 elderly patients." | 3.75 | Probable levetiracetam-associated depression in the elderly: two case reports. ( Bainbridge, JL; Linnebur, SA; Vande Griend, JP, 2009) |
| "A membrane stabilizing effect of endobronchial laser therapy and antioxidative drugs piracetam and solcoseril was studied in 83 patients with chronic bronchitis." | 3.69 | [The efficacy of membrane-stabilizing therapy in patients with chronic obstructive bronchitis]. ( Nikitin, AV; Prozorova, GG; Sil'vestrov, VP; Simvolokov, SI, 1997) |
| "Migraine is not curable, but preventive treatments are usually used to decrease the intensity and frequency of headache attacks." | 2.84 | Levetiracetam in Compare to Sodium Valproate for Prophylaxis in Chronic Migraine Headache: A Randomized Double-Blind Clinical Trial. ( Ghadikolaei, HS; Kashipazha, D; Siavashi, M, 2017) |
| "Levetiracetam was recently approved as adjunctive therapy for partial onset seizures." | 2.70 | A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. ( Chuang, C; Fahn, S; Frucht, SJ; Louis, ED, 2001) |
| " The state correction was carried out by a fortnight administration of placebo and nootropic piracetam (daily dosage 1." | 2.67 | [The systems approach in assessing the efficacy of the pharmacological correction of a state of long-term mental fatigue in military operators]. ( Kudrin, ID; Posokhova, ST; Tikhonov, MN; Ziuban, AL, 1993) |
| "Murine typhus is a systemic febrile illness caused by Rickettsia typhi, a gram-negative, obligate intracellular bacterium." | 2.50 | Murine typhus as a cause of cognitive impairment: case report and a review of the literature. ( Bergamo, DF; Carr, SB; Emmanuel, PJ; Ferreira, JA, 2014) |
| "Piracetam has been shown to improve speech in aphasic patients." | 2.40 | The role of piracetam in the treatment of acute and chronic aphasia. ( Huber, W, 1999) |
| "In four of ten rats, seizure frequency was unaltered by LEV (non-responders)." | 1.42 | Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats. ( Kang, TC; Ko, AR, 2015) |
| " At a LEV dosage of 17, 54, and 108 mg/kg, respectively, the NDO frequency increased from 1." | 1.35 | Effect of antiepileptic agent, levetiracetam, on urodynamic parameters and neurogenic bladder overactivity in chronically paraplegic rats. ( Blok, B; Campeau, L; Corcos, J; Elzayat, EA; Karsenty, G; Padjen, AL, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (15.15) | 18.7374 |
| 1990's | 7 (21.21) | 18.2507 |
| 2000's | 12 (36.36) | 29.6817 |
| 2010's | 9 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kashipazha, D | 1 |
| Ghadikolaei, HS | 1 |
| Siavashi, M | 1 |
| Carr, SB | 1 |
| Bergamo, DF | 1 |
| Emmanuel, PJ | 1 |
| Ferreira, JA | 1 |
| Wiffen, PJ | 1 |
| Derry, S | 1 |
| Moore, RA | 1 |
| Lunn, MP | 1 |
| Ueda, R | 1 |
| Saito, Y | 1 |
| Ohno, K | 1 |
| Maruta, K | 1 |
| Matsunami, K | 1 |
| Saiki, Y | 1 |
| Sokota, T | 1 |
| Sugihara, S | 1 |
| Nishimura, Y | 1 |
| Tamasaki, A | 1 |
| Narita, A | 1 |
| Imamura, A | 1 |
| Maegaki, Y | 1 |
| Fedin, AI | 1 |
| Solov'eva, ÉI | 1 |
| Mironova, OP | 1 |
| Fedotova, AV | 1 |
| Ko, AR | 1 |
| Kang, TC | 2 |
| Konoplya, AI | 1 |
| Laskov, VB | 1 |
| Shul'ginova, AA | 1 |
| Batysheva, TT | 3 |
| Bagir', LV | 2 |
| Kostenko, EV | 2 |
| Artemova, IIu | 2 |
| Bdovichenko, TV | 1 |
| Gazhula, PA | 1 |
| Zhuravleva, EIu | 1 |
| Ismailov, AM | 2 |
| Lisenker, LN | 2 |
| Nesterova, OV | 2 |
| Otcheskaia, OV | 1 |
| Rotor, LD | 2 |
| Khozova, AA | 2 |
| Boĭko, AN | 3 |
| Ivanova, NE | 1 |
| Panuntsev, VS | 1 |
| Artemova, IY | 1 |
| Vdovichenko, TV | 2 |
| Ganzhula, PA | 2 |
| Zhuravleva, EY | 1 |
| Otcheskaya, OV | 1 |
| Elzayat, EA | 1 |
| Campeau, L | 1 |
| Karsenty, G | 1 |
| Blok, B | 1 |
| Padjen, AL | 1 |
| Corcos, J | 1 |
| Vande Griend, JP | 1 |
| Linnebur, SA | 1 |
| Bainbridge, JL | 1 |
| Kim, JE | 1 |
| Choi, HC | 1 |
| Song, HK | 1 |
| Jo, SM | 1 |
| Kim, DS | 1 |
| Choi, SY | 1 |
| Kim, YI | 1 |
| Stroganova, IM | 1 |
| Kiparisov, MA | 1 |
| Ardid, D | 1 |
| Lamberty, Y | 1 |
| Alloui, A | 1 |
| Coudore-Civiale, MA | 1 |
| Klitgaard, H | 1 |
| Eschalier, A | 1 |
| McGavin, CL | 1 |
| John, V | 1 |
| Musser, WS | 1 |
| Pinto, A | 1 |
| Sander, JW | 1 |
| Kabanov, AA | 1 |
| Es'kina, TA | 1 |
| Sheliakina, LA | 1 |
| Shchukin, AI | 1 |
| Volovets, SA | 1 |
| van Vliet, EA | 1 |
| van Schaik, R | 1 |
| Edelbroek, PM | 1 |
| da Silva, FH | 1 |
| Wadman, WJ | 1 |
| Gorter, JA | 1 |
| Bugrova, SG | 1 |
| Novikov, AE | 1 |
| Sobczyk, W | 1 |
| Kudrin, ID | 1 |
| Ziuban, AL | 1 |
| Tikhonov, MN | 1 |
| Posokhova, ST | 1 |
| Prozorova, GG | 1 |
| Sil'vestrov, VP | 2 |
| Simvolokov, SI | 1 |
| Nikitin, AV | 3 |
| Zed, PJ | 1 |
| Loewen, PS | 1 |
| Robinson, G | 1 |
| Huber, W | 1 |
| Frucht, SJ | 1 |
| Louis, ED | 1 |
| Chuang, C | 1 |
| Fahn, S | 1 |
| Dimond, SJ | 1 |
| Scammell, RE | 1 |
| Pryce, IG | 2 |
| Huws, D | 1 |
| Gray, C | 2 |
| Lloyd-Evans, S | 1 |
| Brocklehurst, JC | 1 |
| Palmer, MK | 1 |
| Kinitin, AV | 1 |
| Chesnokova, IV | 3 |
| Sysoeva, LI | 2 |
| Shubina, TI | 1 |
| Zaĭtsev, VP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
5 reviews available for piracetam and Chronic Disease
| Article | Year |
|---|---|
Murine typhus as a cause of cognitive impairment: case report and a review of the literature.
Topics: Acetazolamide; Adolescent; Anticonvulsants; Brain; Chronic Disease; Cognition Disorders; Diagnosis, | 2014 |
Levetiracetam for neuropathic pain in adults.
Topics: Adult; Analgesics; Chronic Disease; Humans; Levetiracetam; Neuralgia; Piracetam; Randomized Controll | 2014 |
Levetiracetam: a new therapeutic option for refractory epilepsy.
Topics: Animals; Anticonvulsants; Chronic Disease; Drug Evaluation; Drug Interactions; Epilepsy; Humans; Lev | 2003 |
Medication-induced headache: overview and systematic review of therapeutic approaches.
Topics: Amitriptyline; Analgesics; Anti-Inflammatory Agents; Chronic Disease; Ergolines; Headache; Humans; M | 1999 |
The role of piracetam in the treatment of acute and chronic aphasia.
Topics: Acute Disease; Aphasia; Cerebrovascular Disorders; Chronic Disease; Humans; Nootropic Agents; Pirace | 1999 |
9 trials available for piracetam and Chronic Disease
| Article | Year |
|---|---|
Levetiracetam in Compare to Sodium Valproate for Prophylaxis in Chronic Migraine Headache: A Randomized Double-Blind Clinical Trial.
Topics: Adolescent; Adult; Analgesics; Chronic Disease; Disability Evaluation; Double-Blind Method; Female; | 2017 |
[Phezam efficacy in patients with chronic cerebral ischemic disease].
Topics: Aged; Brain; Brain Ischemia; Calcium Channel Blockers; Cerebrovascular Circulation; Chronic Disease; | 2005 |
[Effectiveness of parenteral administration of piracetam in acute and chronic consciousness disorders in cerebral arteriosclerosis].
Topics: Acute Disease; Aged; Chronic Disease; Clinical Trials as Topic; Cognition Disorders; Consciousness D | 1980 |
[The systems approach in assessing the efficacy of the pharmacological correction of a state of long-term mental fatigue in military operators].
Topics: Adolescent; Adult; Chronic Disease; Drug Evaluation; Humans; Mental Fatigue; Military Personnel; Per | 1993 |
A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus.
Topics: Adult; Aged; Anticonvulsants; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration | 2001 |
Some effects of piracetam (UCB 6215, Nootropyl) on chronic schizophrenia.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Dichotic Listening Tests; Double-Blind Method; Fem | 1979 |
Trial of 'Piracetam' in chronic schizophrenia.
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Humans; Piracetam; Pyrrolidinones; S | 1978 |
Piracetam in chronic brain failure.
Topics: Arteriosclerosis; Chronic Disease; Dementia; Double-Blind Method; Female; Humans; Male; Piracetam; P | 1979 |
[Experience using nootropil in patients with chronic ischemic heart disease].
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Humans; Male; Middle Aged; | 1989 |
19 other studies available for piracetam and Chronic Disease
| Article | Year |
|---|---|
Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase.
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Bromides; Child; Chronic Disease; Encephalitis; F | 2015 |
[Treatment of asthenic syndrome in patients with chronic brain ischemia: results of the non-interventional observational program TRIUMPH].
Topics: Aged; Aged, 80 and over; Asthenia; Brain Ischemia; Chronic Disease; Female; Humans; Male; Middle Age | 2014 |
Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats.
Topics: Animals; Anticonvulsants; Brain; Chronic Disease; Disease Models, Animal; Endothelin B Receptor Anta | 2015 |
[Immune and oxygen disturbances in patients with chronic cerebral ischemia and their correction].
Topics: Adult; Amino Acids; Antioxidants; Brain Ischemia; C-Reactive Protein; Chronic Disease; Complement C1 | 2015 |
[The use of memotropil for treatment of mild cognitive impairment in out-patients with progressive chronic cerebrovascular disorders].
Topics: Aged; Ambulatory Care; Cerebrovascular Disorders; Chronic Disease; Cognition Disorders; Disease Prog | 2008 |
[The use of vinpotropile in chronic brain ishemia].
Topics: Adult; Aged; Brain Ischemia; Chronic Disease; Drug Combinations; Female; Humans; Male; Middle Aged; | 2008 |
Experience of the out-patient use of memotropil in the treatment of cognitive disorders in patients with chronic progressive cerebrovascular disorders.
Topics: Aged; Ambulatory Care; Cerebrovascular Disorders; Chronic Disease; Cognition Disorders; Disease Prog | 2009 |
Effect of antiepileptic agent, levetiracetam, on urodynamic parameters and neurogenic bladder overactivity in chronically paraplegic rats.
Topics: Animals; Anticonvulsants; Chronic Disease; Dose-Response Relationship, Drug; Female; Levetiracetam; | 2009 |
Probable levetiracetam-associated depression in the elderly: two case reports.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Depression; Epilepsies, Partial; Female; | 2009 |
Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats.
Topics: Animals; Anticonvulsants; Astrocytes; Chronic Disease; Epilepsy; Gliosis; Hippocampus; Interleukin-1 | 2010 |
[Omaron in the restorative treatment of patients with chronic cerebrovascular insufficiency].
Topics: Administration, Oral; Atherosclerosis; Brain Ischemia; Calcium Channel Blockers; Carotid Arteries; C | 2010 |
Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats.
Topics: Acute Disease; Analgesics; Animals; Carbamazepine; Chronic Disease; Constriction, Pathologic; Diabet | 2003 |
Levetiracetam as a treatment for tardive dyskinesia: a case report.
Topics: Adrenergic alpha-Agonists; Anticonvulsants; Antidepressive Agents; Chronic Disease; Clonidine; Depre | 2003 |
Development of tolerance to levetiracetam in rats with chronic epilepsy.
Topics: Animals; Anticonvulsants; Chromatography, Gas; Chronic Disease; Disease Models, Animal; Dose-Respons | 2008 |
[The use of lucetam for improvement of cognitive functions in chronic cerebrovascular insufficiency (clinical and encephalographic study)].
Topics: Adult; Cerebrovascular Disorders; Chronic Disease; Cognition; Cognition Disorders; Disease Progressi | 2007 |
[The efficacy of membrane-stabilizing therapy in patients with chronic obstructive bronchitis].
Topics: Actihaemyl; Adult; Bronchitis; Chronic Disease; Combined Modality Therapy; Disseminated Intravascula | 1997 |
[Immunological and metabolic disorders and the means for their correction in patients with chronic bronchitis].
Topics: Adolescent; Adult; Antibody Formation; Antioxidants; Bronchitis; Chronic Disease; Drug Evaluation; F | 1991 |
[The efficacy of piracetam in treating patients with chronic bronchitis and concomitant atherosclerosis].
Topics: Aged; Arteriosclerosis; Bronchitis; Chronic Disease; Drug Evaluation; Humans; Lipid Peroxidation; Mi | 1990 |
[Correction of metabolic and immunologic disorders in chronic bronchitis with piracetam].
Topics: Adjuvants, Immunologic; Antioxidants; Bronchitis; Chronic Disease; Humans; Leukocyte Count; Lipid Pe | 1990 |